Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311708 · ClinicalTrials.gov registry record
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
A clinical trial of Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by Tenaya Therapeutics.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT06311708 is a study of Arrhythmogenic Right Ventricular Cardiomyopathy that is actively recruiting participants, run by Tenaya Therapeutics. The registered enrollment target is 200 participants, below the 334-participant average among 4 other Arrhythmogenic Right Ventricular Cardiomyopathy trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06311708, a study of Arrhythmogenic Right Ventricular Cardiomyopathy, is actively recruiting participants, sponsored by Tenaya Therapeutics.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Conditions Studied
Study Locations (20)
Other
- Hopital Louis Pradel - Bron
- Nantes University Hospital - Nantes
- Pitié-Salpêtrière Hospital - Paris
- Hôpital Haut-Lévêque - Pessac
- University Hospital Muenster - Münster
- Wuerzburg University Hospital - Würzburg
- Centro Cardiologico Monzino - Milan
- Istituti Clinici Scientifici Maugeri SpA - Pavia
- Skåne University Hospital - Malmo
- The Queen Elizabeth Hospital - Glasgow
- Barts & The London Health NHS Trust - London
- St. George's University Hospitals NHS Foundation Trust - London
California
- University of California San Francisco - San Francisco
Colorado
- University of Colorado, Denver - Aurora
Maryland
- John Hopkins University School of Medicine - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- New York University - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2030-07-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311708
The ClinicalTrials.gov registry entry for NCT06311708 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 334-participant average among 4 other Arrhythmogenic Right Ventricular Cardiomyopathy trials with a reported enrollment target (40% lower). The listed sponsor is Tenaya Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arrhythmogenic Right Ventricular Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT06311708 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06311708 about?
NCT06311708 is a clinical study titled "Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)". This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless ...
What is the current status of trial NCT06311708?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-01-31. Estimated completion is 2030-07-11.
What conditions does trial NCT06311708 study?
This clinical trial studies the following conditions: Arrhythmogenic Right Ventricular Cardiomyopathy.
Who is sponsoring clinical trial NCT06311708?
This trial is sponsored by Tenaya Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311708 being conducted?
This trial has 20 study locations across California, Colorado, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmogenic Right Ventricular Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mayo AVC Registry and Biobank
RECRUITING
-
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
RECRUITING · Phase 1
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
-
Pilot Randomized Trial With Flecainide in ARVC Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.